# SUPPORTING INFORMATION

# Supplementary Tables and Figures

## Table S1 Onset and resolution of ALT/AST elevationsa

|  |  |  |  |
| --- | --- | --- | --- |
| **Patients (%)** | **Placebo(n = 76)** | **CBD25(n = 75)** | **CBD50(n = 73)** |
| **ALT/AST elevations >3  ULN** | **0** | **9/75 (12)** | **19/73 (26)** |
| On valproate | 0 | 7/9 (78) | 15/19 (79) |
| Off valproate | 0 | 2/9 (22) | 4/19 (21) |
| **Time to onset of ALT/AST elevations** |
| Within 30 days | 0 | 6/9 (67) | 14/19 (74) |
| >30 days  | 0 | 3/9 (33) | 5/19 (26) |
| **Resolved ALT/AST elevations** |
| Spontaneously (on treatment) | 0 | 5/9 (56) | 8/19 (42) |
| After CBD/ASM dose reduction | 0 | 3/9 (33) | 7/19 (37) |
| Following discontinuation of trial medication | 0 | 1/9 (11) | 4/19 (21) |

aElevations in ALT/AST levels were determined by laboratory testing, regardless of whether or not they were reported as an adverse event.

Abbreviations: ASM, antiseizure medication; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CBD, cannabidiol; CBD25, cannabidiol 25 mg/kg/day; CBD50, cannabidiol 50 mg/kg/day; ULN, upper limit of normal.

.

## Figure S1. Titration schedule.



aMedication was taken daily in 2 equally divided doses. bNot all patients reached or remained on their assigned dose; mean modal dose during follow-up was 24 mg/kg/day for CBD25 and 36 mg/kg/day for CBD50.

CBD25, cannabidiol 25 mg/kg/day; CBD50, cannabidiol 50 mg/kg/day. Adapted with permission of the author from “Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial,” by Elizabeth A. Thiele et al., *JAMA Neurol*. 2021;78:285-92; supplementary eFigure. 2.